Thursday, 19 Nov 2026 Breaking: “Decorate Janakpur station like a bride”: Janaki Temple Mahant urges grand welcome for first Ayodhya train
BREAKING: Apple launches AI platform | Tesla earnings beat estimates | Nvidia stock surges | Bitcoin crosses major resistance
Business

Pharma industry body urges government to avoid abrupt drug price cuts, backs cancer drug trade margin cap

Pharma industry body urges government to avoid abrupt drug price cuts, backs cancer drug trade margin cap

New Delhi [India], November 19 (ANI): The Organisation of Pharmaceutical Producers of India (OPPI) on Thursday urged the government to avoid abrupt drug price cuts, saying sudden reductions can disrupt investments made over several years. The industry body backed the government's move to cap trade margins on cancer medicines.
Speaking to ANI on the sidelines of the OPPI Annual Summit 2026 on Pharmaceutical Innovation in New Delhi, OPPI Director General Anil Matai said, “We support the government's initiative for trade margin rationalization.” He added, “There should not be abrupt price cuts.”
Matai cited the example of drug prices falling by 20 to 40 per cent overnight to explain why research-based drugmakers want greater predictability in pricing, patent decisions and regulatory processes.
The National Pharmaceutical Pricing Authority (NPPA) capped trade margins at 30 per cent for 137 specified non-scheduled anti-cancer medicines. The revised prices took effect on November 9. The regulator defines the trade margin as the difference between the price at which the manufacturer sells a drug to a stockist or distributor and its maximum retail price, excluding GST.
“So all the companies which were giving margins beyond 30% there you see a significant price reduction,” Matai said. He said companies whose margins were already within the cap could comply without cutting prices.
Matai also called for a reimbursement mechanism for expensive medicines, saying some drugs could remain beyond patients’ reach even after a 50 per cent price cut. “If we have to come out with a system or a mechanism for reimbursing, then this issue will get addressed,” he said.
On drug research, Matai flagged delays linked to objections raised before and after patents are granted. He also called for protection of the safety and efficacy data that drugmakers submit to regulators, saying companies spend years generating those data and that allowing later applicants to rely on them can weaken the incentive to invest in research in India.
“What is the incentive for a global investor to research in innovation in research in India?” he questioned. (ANI)

Tags

Related News

India needs about USD 430 billion in exports over five months to meet FY27 target: Piyush Goyal
Business
India needs about USD 430 billion in exports over five months to meet FY27 target: Piyush Goyal

<p>New Delhi [India], November 19 (ANI): India needs about USD 430 billion in goods and services exports between Novembe...

US jobless claims rise by 1,000 to 203,000, continuing claims climb by 70,000
Business
US jobless claims rise by 1,000 to 203,000, continuing claims climb by 70,000

<p>New Delhi [India], November 19 (ANI): The number of Americans filing new claims for unemployment benefits rose by 1,0...

Test of any reform is whether insurance promise is kept when customer needs it most, says IRDAI Chairman Ajay Seth
Business
Test of any reform is whether insurance promise is kept when customer needs it most, says IRDAI Chairman Ajay Seth

<p>New Delhi [India], November 19 (ANI): Insurance is a promise, and the test of any reform is whether that promise is k...

SEBI preparing guidelines for responsible AI use in capital markets, including disclosures and accountability: KVR Murty
Business
SEBI preparing guidelines for responsible AI use in capital markets, including disclosures and accountability: KVR Murty

<p>Mumbai (Maharashtra) [India], November 19 (ANI): The Securities and Exchange Board of India (SEBI) is preparing to is...

FICCI president urges Indian firms to prepare for India-EU trade pact, says it could take effect by March or April
Business
FICCI president urges Indian firms to prepare for India-EU trade pact, says it could take effect by March or April

<p>New Delhi [India], November 19 (ANI): FICCI President Anant Goenka on Thursday urged Indian businesses to prepare for...

The Board approves major relaxation in EPF withdrawal; Minimum PF balance requirement reduced from 25% to 10%
Business
The Board approves major relaxation in EPF withdrawal; Minimum PF balance requirement reduced from 25% to 10%

<p>New Delhi [India], November 19 (ANI): Dr. Mansukh Mandaviya, Union Minister for Labour & Employment and Youth Affairs...